Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-22.5%||ROE||-25.68%||ROI|
|Current Ratio||12.99||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||36.06 M||Cash From Investing Activities||-40 K||Cash From Operating Activities||-3.79 M||Gross Profit|
|Net Profit||-5.41 M||Operating Profit||-4.29 M||Total Assets||76.05 M||Total Current Assets||75.97 M|
|Total Current Liabilities||5.85 M||Total Debt||Total Liabilities||9.43 M||Total Revenue|
|High 52 week||3.84||Low 52 week||1.92||Last close||2.88||Last change||-1.03%|
|RSI||77.42||Average true range||0.13||Beta||0.6||Volume||310.27 K|
|Simple moving average 20 days||11.78%||Simple moving average 50 days||18.31%||Simple moving average 200 days||-3.21%|
|Performance Week||3.97%||Performance Month||16.13%||Performance Quart||3.23%||Performance Half||-3.03%|
|Performance Year||-8.57%||Performance Year-to-date||50%||Volatility daily||3.02%||Volatility weekly||6.74%|
|Volatility monthly||13.82%||Volatility yearly||47.87%||Relative Volume||298.06%||Average Volume||1.79 M|
|New High||New Low|
2019-03-19 18:16:19 | Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT
2019-03-19 17:23:00 | Why Catalyst Pharmaceuticals Stock Is Popping Today
2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse
2019-03-18 16:52:23 | Catalyst: 4Q Earnings Snapshot
2019-02-28 13:44:28 | U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug
2019-02-28 08:03:00 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
2019-02-21 14:28:05 | Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
2019-02-21 09:00:00 | Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
2019-02-11 14:58:05 | Catalyst Pharma sees net price of drug, once free, topping $300,000
2019-02-06 14:39:06 | Coral Gables company under fire for drug pricing says patient care is 'top priority'
2019-02-05 08:03:00 | Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference
2019-02-04 10:34:04 | U.S. Senator Sanders asks why drug, once free, now costs $375k
2019-01-28 12:22:46 | What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?
2019-01-04 08:03:00 | Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis
2018-12-19 12:32:12 | Should You Buy Catalyst Pharmaceuticals, Inc. CPRX?
2018-12-18 11:40:00 | Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets
2018-12-14 11:42:37 | Does Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Have A Volatile Share Price?
2018-12-11 07:30:00 | Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
2018-11-30 17:42:00 | Why Catalyst Pharmaceuticals Stock Fell Again Today
2018-11-29 16:00:00 | Why Catalyst Pharmaceuticals Stock Is Sinking Today
2018-11-29 09:25:32 | FDA approves new drug developed by Coral Gables company
2018-11-29 08:33:01 | Catalyst's Firdapse Receives FDA Approval for Rare Disease
2018-11-28 18:36:26 | U.S. FDA approves Catalyst Pharma's rare disease drug
2018-11-20 08:39:01 | Do Options Traders Know Something About Catalyst CPRX Stock We Don't?
2018-11-08 17:37:28 | Edited Transcript of CPRX earnings conference call or presentation 8-Nov-18 1:30pm GMT
2018-11-07 18:35:34 | Catalyst: 3Q Earnings Snapshot
2018-10-10 07:30:00 | Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, Analyst Ratings
2018-09-20 12:56:49 | Catalyst Pharmaceuticals Inc’s NASDAQ:CPRX Shift From Loss To Profit
2018-09-20 08:03:00 | Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2018-09-06 11:39:03 | Catalyst CPRX Up 16% Since Last Earnings Report: Can It Continue?
2018-08-30 18:51:07 | Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
2018-08-22 19:03:37 | Why Catalyst Pharmaceuticals CPRX Is a $6 Stock
2018-08-08 06:30:00 | Catalyst Pharmaceuticals, Inc. to Host Earnings Call
2018-08-07 16:44:37 | Catalyst: 2Q Earnings Snapshot
2018-08-06 08:03:00 | Catalyst Pharmaceuticals Expands Commercial Leadership Team
2018-08-01 07:30:00 | New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth, and Expectations for 2018